HC Wainwright Issues Pessimistic Estimate for PVLA Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for Palvella Therapeutics in a report issued on Tuesday, April 1st. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($3.56) for the quarter, down from their previous estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q1 2025 earnings at ($3.56) EPS, Q2 2025 earnings at ($3.79) EPS, Q2 2025 earnings at ($3.79) EPS, Q3 2025 earnings at ($4.05) EPS, Q4 2025 earnings at ($4.33) EPS, Q4 2025 earnings at ($4.33) EPS, FY2025 earnings at ($15.73) EPS, FY2025 earnings at ($15.73) EPS, FY2026 earnings at ($12.67) EPS, FY2026 earnings at ($12.67) EPS, FY2027 earnings at ($13.80) EPS, FY2027 earnings at ($13.80) EPS, FY2028 earnings at ($8.72) EPS, FY2028 earnings at ($8.72) EPS and FY2029 earnings at ($5.23) EPS.

Several other brokerages have also recently commented on PVLA. Jones Trading began coverage on Palvella Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $45.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating on the stock. Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a “buy” rating and a $45.00 target price for the company. Canaccord Genuity Group reissued a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Finally, TD Cowen initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Palvella Therapeutics currently has an average rating of “Buy” and an average price target of $43.50.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $23.98 on Friday. The stock’s 50 day simple moving average is $21.48. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27. The company has a market cap of $264.24 million, a price-to-earnings ratio of -1.98 and a beta of 0.10.

Hedge Funds Weigh In On Palvella Therapeutics

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter valued at $125,000. Toronto Dominion Bank acquired a new stake in shares of Palvella Therapeutics during the fourth quarter worth $159,000. Geode Capital Management LLC acquired a new stake in shares of Palvella Therapeutics during the fourth quarter worth $171,000. Cresset Asset Management LLC bought a new stake in Palvella Therapeutics in the fourth quarter valued at about $251,000. Finally, Renaissance Technologies LLC acquired a new position in Palvella Therapeutics in the fourth quarter valued at about $256,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.